Citations

Clear

3042 citation(s) found for "Kumar, S".

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
Kapoor, Prashant , Kumar, Shaji , Fonseca, Rafaël , Lacy, Martha Q. , Hayman, Suzanne R. , Dispenzieri, Angela , Bergsagel, P. Leif , Dalton, Robert J., Dingli, David , Reeder, Craig B. , Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Stewart, A. Keith, Kyle, Robert A. , Greipp, Philip R., Rajkumar, S. Vincent , Witzig, Thomas E. , Buadi, Francis K. , Gertz, Morie A. , Mıkhael, Joseph , Roy, Vivek , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | March 26, 2009 | Volume: 114 | Issue: 3 | Pages: 518-521

10.1182/blood-2009-01-202010 | PMID 19324902 Get It

Abstract The outcome of patients with multiple myeloma is dictated primarily by cytogenetic abnormalities and proliferative capacity of plasma cells. We studied the outcome after initial therapy with lenalidomide-dexamethasone among 100 newly diagnosed patients, risk-stratified by genetic abnormalities and plasma cell labeling index. A total of 16% had high-risk multiple myeloma, defined by the presence of hypodiploidy, del(13q) by metaphase cytogenetics, del(17p), IgH translocations [t(4;14), or t(14;16)] or plasma cell labeling index more than or equal to 3%. Response rates were 81% vs 89% in the high-risk and standard-risk groups, respectively. The median progression-free survival was shorter in the high-risk group (18.5 vs 36.5 months, P < .001), but overall survival was comparable. Because of unavailability of all tests for every patient, we separately analyzed 55 stringently classified patients, and the results were similar. In conclusion, high-risk patients achieve less durable responses with lenalidomide-dexamethasone compared with standard-risk patients; no significant differences in overall survival are apparent so far. These results need confirmation in larger, prospectively designed studies.
SUPERFICIAL SIDEROSIS: SEALING THE DEFECT
Kumar, Neeraj , Lane, John I. , Piepgras, David G.

Mayo Clinic

Neurology | February 16, 2009 | Volume: 72 | Issue: 7 | Pages: 671-673

10.1212/01.wnl.0000342457.22536.af | PMID 19221303 Get It

Novel Mechanisms in the Regulation of Phosphorus Homeostasis
Berndt, Theresa J., Kumar, Rajiv

Mayo Clinic

Physiology | February 4, 2009 | Volume: 24 | Issue: 1 | Pages: 17-25

10.1152/physiol.00034.2008 | PMID 19196648 Get It

Phosphorus plays a critical role in diverse biological processes, and, therefore, the regulation of phosphorus balance and homeostasis are critical to the well being of the organism. Changes in environmental, dietary, and serum concentrations of inorganic phosphorus are detected by sensors that elicit changes in cellular function and alter the efficiency by which phosphorus is conserved. Short-term, post-cibal responses that occur independently of hormones previously thought to be important in phosphorus homeostasis may play a larger role than previously appreciated in the regulation of phosphorus homeostasis. Several hormones and regulatory factors such as the vitamin D endocrine system, parathyroid hormone, and the phosphatonins (FGF-23, sFRP-4, MEPE) among others, may play a role only in the long-term regulation of phosphorus homeostasis. In this review, we discuss how organisms sense changes in phosphate concentrations and how changes in hormonal factors result in the conservation or excretion of phosphorus.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Kyle, Robert A. , Katzmann, Jerry A., Caporaso, Neil E. , Hayes, Richard B. , Dispenzieri, Angela , Kumar, Shaji , Clark, Raynell, Baris, Dalsu , Hoover, Robert N. , Rajkumar, S. Vincent , Landgren, Ola , Pfeiffer, Ruth M. , Rajkumar, S Vincent , Dispenzieri, Angela , Hayes, Richard B

Mayo Clinic

Blood | January 29, 2009 | Volume: 113 | Issue: 22 | Pages: 5412-5417

10.1182/blood-2008-12-194241 | PMID 19179464 Get It

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell proliferative disorder associated with a life-long risk of progression to multiple myeloma (MM). It is not known whether MM is always preceded by a premalignant asymptomatic MGUS stage. Among 77 469 healthy adults enrolled in the nationwide population-based prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, we identified 71 subjects who developed MM during the course of the study in whom serially collected (up to 6) prediagnostic serum samples obtained 2 to 9.8 years prior to MM diagnosis were available. Using assays for monoclonal (M)–proteins (electrophoresis/immunofixation) and kappa-lambda free light chains (FLCs), we determined longitudinally the prevalence of MGUS and characterized patterns of monoclonal immunoglobulin abnormalities prior to MM diagnosis. MGUS was present in 100.0% (87.2%-100.0%), 98.3% (90.8%-100.0%), 97.9% (88.9%-100.0%), 94.6% (81.8%-99.3%), 100.0% (86.3%-100.0%), 93.3% (68.1%-99.8%), and 82.4% (56.6%-96.2%) at 2, 3, 4, 5, 6, 7, and 8+ years prior to MM diagnosis, respectively. In approximately half the study population, the M-protein concentration and involved FLC-ratio levels showed a yearly increase prior to MM diagnosis. In the present study, an asymptomatic MGUS stage consistently preceded MM. Novel molecular markers are needed to better predict progression to MM in patients with MGUS.
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Vachon, Celine M. , Kyle, Robert A. , Therneau, Terry M. , Foreman, Barbara J., Colby, Colin , Phelps, Tara K., Dispenzieri, Angela , Kumar, Shaji , Katzmann, Jerry A., Rajkumar, S. Vincent , Vachon, Celine M. , Larson, Dirk R. , Rajkumar, S Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | January 29, 2009 | Volume: 114 | Issue: 4 | Pages: 785-790

10.1182/blood-2008-12-192575 | PMID 19179466 Get It

Abstract We examined whether monoclonal gammopathy of undetermined significance (MGUS) is increased in first-degree relatives of multiple myeloma (MM) or MGUS patients. Probands were recruited from a population-based prevalence study (MGUS) and the Mayo Clinic (MM). Serum samples were collected from first-degree relatives older than 40 years and subjected to electrophoresis and immunofixation. The prevalence of MGUS in relatives was compared with population-based rates. Nine-hundred eleven relatives of 232 MM and 97 MGUS probands were studied. By electrophoresis, MGUS was detected in 55 (6%) relatives, and immunofixation identified 28 additional relatives for an age- and sex-adjusted prevalence of 8.1% (95% CI, 6.3 to 9.8). The prevalence of MGUS in relatives increased with age (1.9%, 6.9%, 11.6%, 14.6%, 21.0% for ages 40-49, 50-59, 60-69, 70-79, ≥ 80 years, respectively; P < .001). Using similar MGUS detection methods, there was a higher risk of MGUS in relatives (age-adjusted risk ratio [RR], 2.6; 95% CI, 1.9 to 3.4) compared with the reference population. The increased risk was seen among relatives of MM (RR, 2.0; 95% CI, 1.4 to 2.8) and MGUS probands (RR, 3.3; 95% CI, 2.1 to 4.8). The increased risk of MGUS in first-degree relatives of MGUS or MM patients implies shared environment and/or genetics.
POLYRADICULOPATHY DUE TO METHOTREXATE-INDUCED EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER
Kumar, N. Girish , Sandroni, Paola , Steensma, David P. , Luthra, H. S., Habermann, Thomas M. , Steensma, David P

Mayo Clinic

Neurology | November 10, 2008 | Volume: 71 | Issue: 20 | Pages: 1644-1645

10.1212/01.wnl.0000334757.16882.37 | PMID 19001256 Get It

Evidence for Enhanced Thy-1 (CD90) Expression in Orbital Fibroblasts of Patients with Graves' Ophthalmopathy
Khoo, Teck Kim, Coenen, Michael J., Schiefer, A, Kumar, Seema , Bahn, Rebecca S.

Mayo Clinic

Thyroid | November 3, 2008 | Volume: 18 | Issue: 12 | Pages: 1291-1296

10.1089/thy.2008.0255 | PMID 18976167 Get It

HYPERMANGANESEMIA, HEREDITARY HEMORRHAGIC TELANGIECTASIA, BRAIN ABSCESS: THE HEPATIC CONNECTION
Boeve, B. F., Cowl, Clayton T. , Ellison, Jay W., Kamath, Priyatham, Swanson, Karen L., Kumar, Naveen

Mayo Clinic

Neurology | September 29, 2008 | Volume: 71 | Issue: 14 | Pages: 1118-1119

10.1212/01.wnl.0000326959.44088.e0 | PMID 18824676 Get It

Many facets of bortezomib resistance/susceptibility
Kumar, Shaji , Rajkumar, S. Vincent , Rajkumar, S Vincent

Mayo Clinic

Blood | September 8, 2008 | Volume: 112 | Issue: 6 | Pages: 2177-2178

10.1182/blood-2008-07-167767 | PMID 18779399 Get It

Comparison of Measured and Calculated Bicarbonate Values
Kumar, Vivek , Karon, Brad S.

Mayo Clinic

Clinical Chemistry | August 28, 2008 | Volume: 54 | Issue: 9 | Pages: 1586-1587

10.1373/clinchem.2008.107441 | PMID 18755915 Get It